​

CAMP4 Therapeutics (CAMP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CAMP Stock Forecast

CAMP4 Therapeutics (CAMP) stock forecast, based on 24 Wall Street analysts, predicts a 12-month average price target of $9.75, with a high of $15.00 and a low of $6.00. This represents a 162.10% increase from the last price of $3.72.

- $3 $6 $9 $12 $15 High: $15 Avg: $9.75 Low: $6 Last Closed Price: $3.72

CAMP Stock Rating

CAMP4 Therapeutics stock's rating consensus is Buy, based on 24 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (66.67%), 7 Hold (29.17%), 1 Sell (4.17%), and 0 Strong Sell (0.00%).

Buy
Total 24 1 7 16 0 Strong Sell Sell Hold Buy Strong Buy

CAMP Price Target Upside V Benchmarks

TypeNameUpside
StockCAMP4 Therapeutics162.10%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts245
Avg Price Target$9.00$9.75$9.10
Last Closing Price$3.72$3.72$3.72
Upside/Downside141.94%162.10%144.62%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2637---10
Oct, 2625---7
Sep, 2625---7
Aug, 2625---7
Jul, 2625---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 23, 2026Tiago FauthRaymond James$10.00$3.39194.99%168.82%
Oct 15, 2026Needham$8.00$3.43133.24%115.05%
Sep 29, 2026Keay NakaeChardan Capital$6.00$3.8555.84%61.29%
Aug 14, 2026UBS$15.00$4.51232.59%303.23%
Jun 10, 2026Keay NakaeChardan Capital$6.50$4.0162.09%74.73%
Oct 02, 2025Cantor Fitzgerald$7.00$2.95137.29%88.17%
Nov 05, 2024Mani ForooharLeerink Partners$17.00$9.6077.08%356.99%
Nov 05, 2024Edward TenthoffPiper Sandler$18.00$9.6087.50%383.87%
Aug 16, 2022Anthony StossCraig-Hallum$10.00$5.8072.41%168.82%
Jun 24, 2022Jerry RevichGoldman Sachs$5.00$4.931.42%34.41%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2026Raymond JamesBuyStrong Buyinitialise
Oct 15, 2026NeedhamNeutralBuyinitialise
Oct 05, 2026OppenheimerOutperforminitialise
Sep 29, 2026Cantor FitzgeraldOverweightOverweighthold
Aug 14, 2026Piper SandlerOverweightOverweighthold
Apr 14, 2026Rodman & RenshawBuyinitialise
Mar 06, 2026Cantor FitzgeraldOverweightOverweighthold
Dec 11, 2025Cantor FitzgeraldOverweightOverweighthold
Oct 02, 2025Cantor FitzgeraldOverweightinitialise
Sep 15, 2025Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 $2 Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27
Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27
Reported--$-4.07----
Avg Forecast$0.77$-2.39$-5.27$-2.10$0.95$-2.42-
High Forecast$0.78$-2.39$-5.27$-1.29$1.01$-2.38-
Low Forecast$0.75$-2.39$-5.27$-3.23$0.86$-2.46-
Surprise %---22.77%----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27
Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27
Reported--$350.00K----
Avg Forecast$295.88M$295.08M$237.48M$229.10M$252.01M$291.96M$152.47M
High Forecast$298.80M$295.08M$237.48M$241.38M$264.74M$291.96M$152.47M
Low Forecast$291.97M$295.08M$237.48M$216.83M$239.28M$291.96M$152.47M
Surprise %---99.85%----

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27
Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27
Reported--$-49.29M----
Avg Forecast$-55.33M$-88.56M$-101.35M$-77.75M$34.69M$-89.58M-
High Forecast$-44.26M$-88.56M$-81.08M$-47.71M$37.36M$-88.11M-
Low Forecast$-66.39M$-88.56M$-121.62M$-119.61M$32.01M$-91.04M-
Surprise %---51.37%----

CAMP Forecast FAQ

Is CAMP4 Therapeutics stock a buy?

CAMP4 Therapeutics stock has a consensus rating of Buy, based on 24 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 7 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that CAMP4 Therapeutics is a favorable investment for most analysts.

What is CAMP4 Therapeutics's price target?

CAMP4 Therapeutics's price target, set by 24 Wall Street analysts, averages $9.75 over the next 12 months. The price target range spans from $6 at the low end to $15 at the high end, suggesting a potential 162.10% change from the previous closing price of $3.72.

How does CAMP4 Therapeutics stock forecast compare to its benchmarks?

CAMP4 Therapeutics's stock forecast shows a 162.10% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for CAMP4 Therapeutics over the past three months?

  • November 2026: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is CAMP4 Therapeutics’s EPS forecast?

CAMP4 Therapeutics's average annual EPS forecast for its fiscal year ending in November 2024 is $-2.1, marking a -48.40% decrease from the reported $-4.07 in 2023. Estimates for the following years are $0.95 in 2025, $-2.42 in 2026, and $0 in 2027.

What is CAMP4 Therapeutics’s revenue forecast?

CAMP4 Therapeutics's average annual revenue forecast for its fiscal year ending in November 2024 is $229.1M, reflecting a 65357.43% increase from the reported $350K in 2023. The forecast for 2025 is $252.01M, followed by $291.96M for 2026, and $152.47M for 2027.

What is CAMP4 Therapeutics’s net income forecast?

CAMP4 Therapeutics's net income forecast for the fiscal year ending in November 2024 stands at $-77.748M, representing an 57.73% increase from the reported $-49.291M in 2023. Projections indicate $34.69M in 2025, $-89.576M in 2026, and $0 in 2027.